Regarding cost-effectiveness, the HCC-Check index incorporates markers (CK-1, EMA) that may not be part of routine liver disease panels, potentially increasing upfront laboratory costs compared to AFP testing alone. The gene discussed is AFP; the disease is hepatocellular carcinoma.